The COBIOPHAD project targets the development of a highly sensitive, selective, and multiplexed diagnostic device to provide a quick and inexpensive in vitro test to address the most prevalent drug hypersensitivity to betalactams antibiotics, (BLCs). During a retrospective study, BLC structures involved in drug hypersensitivity will be identified from sera of allergic patients (versus controls) and coupled on the device. A prospective study will be performed for the recruitment of samples corresponding to patients with known IgE hypersensitivity to BLCs based on results from allergy tests and clinical history. Controls will include: non-allergic individuals with known tolerance to betalactams. The samples will be used for the validation of the COBIOPHAD device in real settings.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
145
immediate hypersensitivity to BLC by In vitro diagnosis
University hospital of Montpellier
Montpellier, France
Sensitivity of the COBIOPHAD device in diagnosing immediate hypersensitivity to BLC
Time frame: up to 1 hour
Specificity of the COBIOPHAD device in diagnosing immediate hypersensitivity to BLC
Time frame: up to 1 hour
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.